Tvardi Therapeutics, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Tvardi Therapeutics announced July 30, 2026 that it has selected ulcerative colitis (UC) as the initial indication for TTI-109, a STAT3 inhibitor oral small molecule. The company completed a Phase 1 healthy volunteer study showing TTI-109 reduced multiple immune cell populations (Th17 up to 76%, Tfh up to 43%, B cells up to 71%) implicated in UC pathology across an active dose range of 250–500 mg BID. Tvardi plans to initiate a Phase 2 UC trial in 2027 (pending IND clearance and funding), targeting moderate-to-severe patients with prior inadequate biologic or JAK inhibitor response, in a market estimated at ~$3B (US) to $9B (global) with 1.25M diagnosed US patients; 70% do not achieve remission with existing therapies.
Why this rating
Indication selection and Phase 1 pharmacodynamic data support clinical progress, but company must secure IND clearance and additional funding; UC opportunity is large but competitive; significance modest relative to $207M market cap.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.